BALPHARMA.NSBALPHARMA.NSNSE
Loading
Year-over-year SG&A expense growth
Latest
0.00%
↑ 100% vs avg
Percentile
P56
Within normal range
Average
-2.45%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | -9.02% |
| Q4 2024 | 0.00% |
| Q3 2024 | -100.00% |
| Q2 2024 | -11.03% |
| Q1 2024 | 22.46% |
| Q4 2023 | -21.36% |
| Q3 2023 | 48.46% |
| Q2 2023 | -24.89% |
| Q1 2023 | 26.30% |
| Q4 2022 | -13.57% |
| Q3 2022 | 14.91% |
| Q2 2022 | -3.22% |
| Q1 2022 | 12.95% |
| Q4 2021 | -18.79% |
| Q3 2021 | 79.66% |
| Q2 2021 | -30.73% |
| Q1 2021 | -5.09% |
| Q4 2020 | 6.56% |
| Q3 2020 | 9.37% |
| Q2 2020 | -18.30% |
| Q1 2020 | -5.76% |
| Q4 2019 | -8.70% |
| Q3 2019 | 1.07% |
| Q2 2019 | -2.03% |
| Q1 2019 | 3.92% |
| Q4 2018 | -0.38% |
| Q3 2018 | 10.31% |
| Q2 2018 | -18.59% |
| Q1 2018 | 28.17% |
| Q4 2017 | -0.71% |
| Q3 2017 | -3.56% |
| Q2 2017 | -9.92% |
| Q1 2017 | 14.34% |
| Q4 2016 | -2.00% |
| Q3 2016 | 14.91% |
| Q2 2016 | -12.43% |
| Q1 2016 | 28.53% |